# Oruka Therapeutics Inc. (ORKA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $92.51, market value $6.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Oruka Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.1×**. The shares trade at 5.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.7%** (5-yr avg -26.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -22.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -1.1%**. Each dollar of assets produces -1.1% of profit.

## Financial health
- **Current ratio: 22.37** (quick 22.37). Current assets cover the next year's liabilities 22.37 times.

## Dividends
- **Dividend: none**. Oruka Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Oruka Therapeutics Inc.; the consensus is strong_buy, with an average price target of $155.00 (+68% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 518.0%** (YTD 205.2%, 3-mo 53.8%). The shares are up 518.0% over twelve months including dividends.
- **From 52-week high: -19.9%** (530.6% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 1.44** (volatility 76%). Beta of 1.44 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ORKA · Page: https://foliofundamentals.com/stocks/orka

Not investment advice.